Review

Pancreas Transplantation: Lessons Learned From a Decade of Experience at Wake Forest Baptist Medical Center

Jeffrey Rogers¹, Alan C. Farney¹, Samer Al-Geizawi¹, Samy S. Iskandar², William Doares³, Michael D. Gautreaux¹, Lois Hart¹, Scott Kaczmorski³, Amber Reeves-Daniel⁴, Stephanie Winfrey¹, Mythili Ghanta⁴, Patricia L. Adams⁴, Robert J. Stratta¹

Manuscript submitted April 4, 2011; resubmitted May 4, 2011; accepted May 8, 2011.

Keywords: alemtuzumab, mycophenolate mofetil, pancreas transplantation, portal-enteric, rabbit anti-thymocyte globulin, simultaneous kidney-pancreas transplantation, tacrolimus, type 2 diabetes

Abstract

This article reviews the outcome of pancreas transplantations in diabetic recipients according to risk factors, surgical techniques, and immunosuppression management that evolved over the course of a decade at Wake Forest Baptist Medical Center. A randomized trial of alemtuzumab versus rabbit anti-thymocyte globulin (rATG) induction in simultaneous kidney-pancreas transplantation (SKPT) at our institution demonstrated lower rates of acute rejection and infection in the alemtuzumab group. Consequently, alemtuzumab induction has been used exclusively in all pancreas transplantations since February 2009. Early steroid elimination has been feasible in the majority of patients. Extensive experience with surveillance pancreas biopsies in solitary pancreas transplantation (SPT) is described. Surveillance pancreas biopsy-directed immunosuppression has contributed to equivalent long-term pancreas graft survival rates in SKPT and SPT recipients at our center, in contrast to recent registry reports of persistently higher rates of immunologic pancreas graft loss in SPT. Furthermore, the impact of donor and recipient selection on outcomes is explored. Excellent results have been achieved with older (extended) donors and recipients, in recipients of organs from donation after cardiac death donors managed with extracorporeal support, and in African-American patients. Type 2 diabetics with detectable C-peptide levels have been transplanted successfully with outcomes comparable to those of insulinopenic diabetics. Our experiences are discussed in the light of findings reported in the literature.

Fulltext: HTML , PDF (411KB)

This article has been cited by other articles:

	Pancreas transplantation with enteroanastomosis to native duodenum poses technical challenges-but offers improved endoscopic access for scheduled biopsies and therapeutic interventions Horneland R, Paulsen V, Lindahl JP, Grzyb K, Eide TJ, Lundin K, Aabakken L, Jenssen T, Aandahl EM, Foss A, Oyen O Am J Transplant 2015. 15(1):242-250
	Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin Stratta RJ, Rogers J, Orlando G, Farooq U, Al-Shraideh Y, Doares W, Kaczmorski S, Farney AC Expert Opin Biol Ther 2014. 14(12):1723-1730
	Pancreas Transplantation in C-Peptide Positive Patients: Does "Type" of Diabetes Really Matter? Stratta RJ, Rogers J, Farney AC, Orlando G, El-Hennawy H, Gautreaux MD, Reeves-Daniel A, Palanisamy A, Iskandar SS, Bodner JK J Am Coll Surg 2014. In press
	5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation Stratta RJ, Rogers J, Orlando G, Farooq U, Al-Shraideh Y, Farney AC Transplant Proc 2014. 46(6):1928-1931
	Similar results with solitary pancreas transplantation compared with simultaneous pancreas-kidney transplantation in the new millennium Stratta RJ, Farney AC, Orlando G, Farooq U, Al-Shraideh Y, Rogers J Transplant Proc 2014. 46(6):1924-1927
	Evaluation of insulin independence using 11C-methionine positron emission tomography after living-donor and brain-dead donor pancreas transplantation Otsuki K, Yoshikawa K, Kenmoshi T, Akutsu N, Maruyama M, Asano T, Saigo K, Hasegawa M, Aoyama H, Matsumoto I, Ito T, Uchino Y Transplant Proc 2014. 46(6):1913-1916
	Pancreas transplantation: The Wake Forest experience in the new millennium Rogers J, Farney AC, Orlando G, Iskandar SS, Doares W, Gautreaux MD, Kaczmorski S, Reeves-Daniel A, Palanisamy A, Stratta RJ World J Diabetes 2014. 5(6):951-961
	Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3 van der Meulen T, Huising MO Rev Diabet Stud 2014. 11(1):115-132
	Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective Stratta RJ, Farney AC, Rogers J, Orlando G Expert Rev Clin Immunol 2014. 10(1):117-132
	Pancreas Transplantation in African American Compared to Non African American Patients: Does Recipient Ethnicity Influence Outcomes? Stratta RJ, Farney AC, Orlando G, Farooq U, Al-Shraideh Y, Rogers J Diabetes Pancreas 2014. 1(1):1-8
	Pancreas Transplantation with Systemic-Enteric Drainage when Portal-Enteric Drainage is Contraindicated Stratta RJ, Farney AC, Orlando G, Farooq U, Al-Shraideh Y, El-Hennawy H, Rogers J Pancreat Disord Ther 2014. 4:2
	Pancreas graft survival in simultaneous pancreas-kidney versus pancreas-after-kidney and pancreas alone transplantations: a single institution experience Montiel-Casado MC, Perez-Daga JA, Aranda-Narvaez JM, Fernandez-Burgos I, Sanchez-Perez B, Leon-Diaz FJ, Cabello-Diaz M, Rodriguez-Burgos D, Hernandez-Marrero D, Santoyo-Santoyo J Transplant Proc 2013. 45(10):3609-3611
	Emerging trends for radioimmunotherapy in solid tumors Jain M, Gupta S, Kaur S, Ponnusamy MP, Batra SK Cancer Biother Radiopharm 2013. 28(9):639-650
	Pancreas transplantation, antibodies and rejection: where do we stand? de Kort H, Roufosse C, Bajema IM, Drachenberg CB Curr Opin Organ Transplant 2013. 18(3):337-344
	Steroid-free chronic immunosuppression in renal transplantation Steiner RW Curr Opin Nephrol Hypertens 2012. 21(6):567-573
	Distinctive morphological features of antibody-mediated and T-cell-mediated acute rejection in pancreas allograft biopsies Papadimitriou JC, Drachenberg CB Curr Opin Organ Transplant 2012. 17(1):93-99